Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIFY: Glofitamab + R/G-CHOP in Frontline Richter Syndrome
NCT06186648Phase 2Recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Mar 2024
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in Richter's syndrome (RS), sponsored by French Innovative Leukemia Organisation. Started Mar 2024; status: recruiting.
02
Drugs
glofitamab
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT06186648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186648.